Skip to main content
PLOS Computational Biology logoLink to PLOS Computational Biology
. 2021 Sep 7;17(9):e1009365. doi: 10.1371/journal.pcbi.1009365

Ascension of Chlamydia is moderated by uterine peristalsis and the neutrophil response to infection

Torrington Callan 1, Stephen Woodcock 1,*, Wilhelmina May Huston 2,*
Editor: Janneke Heijne3
PMCID: PMC8448331  PMID: 34492008

Abstract

Chlamydia trachomatis is a common sexually transmitted infection that is associated with a range of serious reproductive tract sequelae including in women Pelvic Inflammatory Disease (PID), tubal factor infertility, and ectopic pregnancy. Ascension of the pathogen beyond the cervix and into the upper reproductive tract is thought to be necessary for these pathologies. However, Chlamydia trachomatis does not encode a mechanism for movement on its genome, and so the processes that facilitate ascension have not been elucidated. Here, we evaluate the factors that may influence chlamydial ascension in women. We constructed a mathematical model based on a set of stochastic dynamics to elucidate the moderating factors that might influence ascension of infections in the first month of an infection. In the simulations conducted from the stochastic model, 36% of infections ascended, but only 9% had more than 1000 bacteria ascend. The results of the simulations indicated that infectious load and the peristaltic contractions moderate ascension and are inter-related in impact. Smaller initial loads were much more likely to ascend. Ascension was found to be dependent on the neutrophil response. Overall, our results indicate that infectious load, menstrual cycle timing, and the neutrophil response are critical factors in chlamydial ascension in women.

Author summary

Modelling informs elements of the disease process that are difficult to evaluate due to the complexity and rareness of these factors in human studies. Previous research has led to significant advances in understanding the role of the immune system and pathogen characteristics in the biology of Chlamydia trachomatis. Here we combine this body of knowledge to build a model that allows us to understand how and when Chlamydia trachomatis might progress to the upper reproductive tract in women. Elements of the natural reproductive cycle and immune system were found to be important in moderating the disease process in women.

Introduction

There is considerable evidence to indicate that Chlamydia trachomatis is one of the aetiological agents responsible for Pelvic Inflammatory Disease (PID), and that women who experience PID are more likely to experience tubal factor infertility and ectopic pregnancy [14]. Laparoscopic, histological and molecular evidence has indicated that infection can be present in the fallopian tubes, even when non-detectable at the cervix, the primary site of infection [5]. It is suggested that the development of tubal pathology is a result of a chlamydial infection ascending into the upper reproductive tract combined with a damaging pro-inflammatory response to the pathogen [6].

While the proportion of infections that ascend are not known, there are estimates on the frequency of damaging pathology. In the POPI trial, 9.5% women with a chlamydial infection developed PID [1]. A longitudinal study of 1844 women with laparoscopically confirmed PID (all aetiologies) found that approximately 30% experience tubal factor infertility [3]. Ascension of Chlamydia trachomatis into the upper genital tract can occur without necessarily developing pathology. The relatively low rate of pathology development in women with infections [7] suggests that a number of host and pathogen factors moderate ascension, such as menstrual cycle, stage of infection, immune status (and other influential factors not considered in this study, such as genotypic factors (host and pathogen), cellular exit strategies of the pathogen (lysis or extrusions) and host microbiome composition). The infectious load (the amount of infection when the infection is first received) may also determine the likelihood of ascension. Maxion et al. described how the infectious load of Chlamydia muridarum in mice was more likely to result in viable bacteria in the oviduct when the animals received lower infecting doses [8]. Higher infecting loads appeared to result in an immune profile in favour of cells associated with the innate immune response. This study found the response of immune cells (innate and adaptive) was independent of location (lower or upper genital tract) for the relationship with infecting load. The findings from this study suggested that innate immune cells contribute to the control of ascending infection, such that the immune response for high infectious loads of bacteria was sufficient to prevent ascension into the upper genital tract, but not so for lower loads.

A comprehensive review identified an association between infectious load, specimen type, and anatomical site of infection [9]. However, the evidence was unclear for the role of infectious load in ascending infection. An experiment on the effects of infectious load in female mice found that higher inoculating doses ascended to the upper genital tract more rapidly [10]. However, in the experimental protocol, mice were given 2.5g of medroxyprogesterone acetate 7 days before infection, and so the interplay between initial load and timing of the menstrual cycle was not evaluated. Only one study [11] looked at the relationship between load at the cervix and PID diagnosis, which found an association between higher load and PID. However, the study design was cross sectional, and so a causal interpretation cannot be made.

All chlamydiae share a unique biphasic developmental cycle, where infectious extracellular elementary bodies (EBs) enter cells and differentiate into replicative reticulate bodies (RBs). After several rounds of replication, RBs differentiate back into EBs and are released from the host cell, in order to infected neighbouring cells [12]. Each host (humans, guinea pig, mice etc.) generally has a distinct species of Chlamydia, and there are 12 species currently identified but the overall biphasic developmental cycle process is consistent throughout the genus. The Chlamydiae do not appear to encode a specific mechanism for movement on its genome. A one-dimensional spatiotemporal model described the population dynamics of chlamydial particles, infected and uninfected epithelial cells, and with movement that was determined by a diffusion coefficient in an idealised representation of the cervix, with random diffusion at about 10–4 μm2 s-1 (with an uncertainty of an order of magnitude) in the elementary body form (EB) [13, 14]. The model demonstrated that the peak infection load and time to clearance was a function of the movement of Chlamydia (C.) trachomatis, and that increased motility may lead to stronger host immune response. However, the scale of the diffusion term, in comparison to the length of the cervix implies that diffusion of the elementary bodies is an implausible process for ascension.

A model for movement or ascension has been proposed by which polymorphonuclear leukocytes (PMNs) infiltrated the conjunctival epithelium following a guinea pig infection with Chlamydia caviae [15]. The response was in the early stages of the infection, which concords with the previously described critical role of neutrophils in controlling the early stage of an infection [16]. The PMN response was observed to result in detached superficial epithelia from the mucosa, including infected cells and elementary bodies that remained healthy and intact during the process. It was suggested by Rank et al. that this response was a defensive mechanism from the perspective of the host organism in that it allows for infected cells that have been ejected from the epithelium to be cleared from the infection site. Further, it was proposed that from the perspective of the pathogen, this process allowed for movement away from infected sites where there is a lack of susceptible uninfected cells, transporting to new infection sites via fluid dynamics or tissue movement. Movement and secretion of materials via fluid dynamics in the genital tract is governed by uterine peristalsis. The interplay of peristaltic contractions and ascension of sexually transmitted infections has not been examined and represents a crucial gap in current understanding.

It has been established that there is bi-directionality of the uterine peristalsis dependent on the stage of the menstrual cycle. In work conducted Kunz and Leyendecker (2001), vaginal sonography of uterine peristalsis in women has been used to characterise the dynamics of rapid sperm transport [17]. They found an increase in the frequency and intensity of subendometrial and myometrial peristaltic waves during the follicular phase of the menstrual cycle. The number of waves in the fundo-cervical direction decreased and waves in the cervico-fundal direction increased at this stage of the cycle, suggesting that sperm transport is facilitated by these uterine conditions, and that the extent of migration is increased with the progression of the follicular phase.

It is therefore plausible that the immune response which detaches infected cells from the epithelium and into the cervical canal can result in the transport of infected cells and elementary bodies via peristalsis into higher regions of the genital tract. Since the direction and intensity of peristaltic movement is dependent on the menstrual cycle, the stage of the menstrual cycle at infection could be one governing factor in determining which women experience infections that ascend or descend the genital tract, although it may be further impacted by the infectious burden (as explored in this model)

The phenomena described above could be combined to provide a process for infective chlamydial bodies to enter into the genital tract and be transported to the upper reproductive tract via peristalsis. From there, the infection cycle described above could start, with pro-inflammatory immune responses following the infection sites to the upper genital tract. In this work, we represent this process with stochastic model of the dynamics of a chlamydial infection, the associated host response, and the movement of infectious material. This allows us to better appreciate the complex, dynamic, and nonlinear interactions between the neutrophil response, the infectious load, and the menstrual cycle that moderate chlamydial ascension. Elucidating the processes involved in chlamydial ascension will provide a better understanding of the pathogenesis of C. trachomatis associated PID and infertility. In turn, the moderating factors could enable more specific testing for at-risk women, or development of other interventions when infections are diagnosed.

Methods

Developing a stochastic model to determine the relative influence of factors that moderate ascension

We developed a stochastic model of C. trachomatis and infected cells in two compartments; the cervical epithelium and cervical canal. The structure of the model is informed by previous mathematical modelling studies of within-host chlamydial dynamics [13, 18], and by synthesis of the literature on the chlamydial developmental cycle and host cell interactions. The model developed for this study extends previous models in order to incorporate elements specific to ascension (such as peristalsis, neutrophil ejections, epithelial and cervical elements) and stochastic elements to incorporate uncertainty. Fig 1 displays the host cell interactions that we represent in our model in order to evaluate the moderating impact of each on ascension.

Fig 1. The proposed model of chlamydial ascension.

Fig 1

The figure depicts the female reproductive tract and elements that were evaluated in their moderating impact of ascension. The factors evaluated were the chlamydial cell cycle, the host and pathogen interactions including the immune system response and the ejection of infectious material from the epithelium, and the effect of peristalsis in moving material either away or towards the upper reproductive tract depending on the stage of the menstrual cycle. Fig 1 was created with BioRender.com.

We infer parameters for our model from plausible prior distributions (Table 1). In turn, prior distributions are parameterised where possible, using values from previous modelling studies. Transitions are stochastic meaning realisations of the model permit variable outcomes. This allows us to infer behaviour about an infection over a broad range of plausible parameter values, including phenomena not explicitly represented in the model.

Table 1. Parameters incorporated in the model and values assigned for this study.

Parameter Meaning Distribution* Value Supporting Literature
γ1,innate, γ1,adaptive Death rate of elementary bodies (EBs) (per minute) due to the innate and adaptive immune response Truncated Gamma 1, 100, τ1 [13, 18, 22, 23]
γ2,innate, γ2,adaptive Death rate of infected cells (per minute) due to immune response Truncated Gamma 1, 100, τ2 [13, 18, 22, 23]
τ1 Threshold of EBs at which immune system increases Negative Binomial 5000, σ1 Assumed
τ2 Threshold of infected cells at which immune system increases Negative Binomial 150, σ2 Assumed
σ1 Variance of the threshold parameter Beta 1, 1 Assumed (hyperparameter)
σ2 Variances of the threshold parameter Beta 1, 1 Assumed (hyperparameter)
κ1 Rate of inclusion of EBs (per minute) into new infected cells Gamma 1, 100 [13, 18, 22, 23]
κ2 Rate of burst of infected cells (per minute) to new EBs Gamma 1, 100 [13, 18, 22, 23]
α Rate of migration of infectious material due to the neutrophil response Gamma 1, 100 Informed by [15]
I Number of new inclusions of infected cells Negative Binomial 10, σ4 [13, 18, 22, 23]
B Number of new EBs in each burst event Negative Binomial 350, σ3 Mean and dispersion chosen to match the 200–500 nominal range as per [13, 18, 22, 23]
M 1 Number of bacteria per migration event Negative Binomial 100, σ5 Informed by [15]
M 2 Number of infected cells per migration event Negative Binomial 10, σ6 Informed by [15]
σ3 Variance of the inclusion size Beta 2, 2 Mean and dispersion chosen to match the 200–500 nominal range as per [13, 18, 22, 23]
σ4 Variance of the burst size Beta 2, 2 Assumed (hyperparameter)
σ5 Variance of the migration for EBs Beta 1, 1 Assumed (hyperparameter)
σ6 Variances of the migration for infected cells Beta 1, 1 Assumed (hyperparameter)
γ3,fixed Rate of removal (per minute) of infectious material due to the intensity of peristaltic contractions Gamma 1, 1 Assumed (unique to this study)

*Details on the parameterisation used for each of the distributions in the model can be found in the S1 Text and S1 Fig.

Finally, the simulations are classified by a binary condition that reflects if the population of infectious material in the cervical canal compartment is non-zero at the endpoint of the simulation. If there is infectious material present (i.e. non-zero in the cervical canal), then ascension is said to occur in that iteration. This outcome is then used to determine relationships between the parameters of the process and the proportion of simulations where ascension occurred (reflecting peristalsis towards the fundus and live infectious material in the cervical canal). Relationships between the parameter values and the outcome are graphically summarised using natural splines. Each simulation is begun with a fixed amount of time remaining before peristaltic contractions move fluid in the cervical canal upwards, causing any infectious material to ascend. We stop each simulation at the moment when peristalsis causes material to begin ascending, with the assumption that any material in the cervical canal at this point will ascend.

Defining the process

There are two entities of interest in this modelling exercise, extracellular chlamydial elementary bodies (EBs) and infected cells containing chlamydial reticulate bodies (RBs) and EBs [12]. We denote X{C1,t},X{C2,t},Y{C1,t},Y{C2,t} as random variables denoting the number of extracellular chlamydia (represented as X) and infected cells (represented as Y) in the epithelium and cervical canal respectively (represented by the subscripts C1, C2). The model assumes that infected cells produce extracellular bacteria in an instantaneous burst, as opposed to a continuous process, which is important to note as this choice may impact the behaviour of generated quantities of the model [19].

C. trachomatis has two distinct exit strategies from a cell, lysis and extrusions, which are mediated by distinct mechanisms [20]. Extruded chlamydial inclusions may exit the cell slower than what occurs via lysis in the rate of exit, and the amount of pathogen released from the cell may differ (albeit this difference is likely subtle compared to the other parameters we explore here). Further, these factors governing chlamydial cell exit may vary by serovar type and various host specific factors. Therefore, we utilise broad parameter ranges over the function of extracellular C. trachomatis in order to represent the variation attributable to these factors without explicitly representing them. To this end, there is only one type of extracellular C. trachomatis represented in the model, although we recognise that there are many other potentially influential factors in the process.

We utilise the framework of previous models of chlamydial infections by Wilson to develop our model [18]. The realised outcomes of a particular sample path in a model of C. trachomatis is proposed to be strongly influenced by the random elements [21], hence our model incorporates stochasticity. Representing the process as a stochastic model allows us to represent the uncertainty attributable to other factors that are believed to be important in moderating infections, such a host and pathogen genotype and the cervico-vaginal microbiome.

For the ascension model, we extend the dynamics of the process to include ejection from the epithelia into the cervical canal. We denote with the subscript C1 for infected cells and EBs in the epithelium, and C2 for infectious units in the cervical canal. The scheme of the process can be represented as follows (following the convention of Pearson et al. [19].

XC1rateγ1(EBsperminute)
YC1rateγ2(infectedcellsperminute)
IXC1YC1rateκ1(EBsperminute)
YC1BXC1rateκ2(infectedcellsperminute)
M1XC1M1XC2rateα(EBsperminute)
M2YC1M2YC2rateα(infectedcellsperminute)
XC2rateγ3(EBsperminute)
YC2rateγ3(infectedcellsperminute)
YC2BXC2rateκ3(infectedcellsperminute)

The vector (X{C1,t},X{C2,t},Y{C1,t},Y{C2,t}) represents the current state vector of the process. The empty set ∅ is used to denote an infectious body (EB or infectious cell) that has been removed by the immune system or peristaltic movement. For this model, we have possible transitions that correspond to the removal of infectious material: (-1, 0, 0, 0) representing the death of an extracellular EB, (0, -1, 0, 0) representing the death of an epithelial infected cell, and (0, 0, -1, -1) representing the removal of EBs and infected cells in the cervical canal.

I(t), B(t) are random variables that determine the number of bacteria required to form an infectious unit, and the number of bacteria formed by a bursting event. M1(t), M2(t) are random variables describing the ejection from the epithelium to the cervical canal of EBs and infected cells respectively.

The trading between infectious material in the epithelium is characterised by (-I(t), 1, 0, 0), where I(t) EBs from an inclusion to produce one infected cell. Conversely, infected cells can burst to produce B(t) new EBs, represented by (B(t), -1, 0, 0). Ejection is represented by (−M1(t), −M2(t), M1(t), M2(t)). Infected cells in the cervical canal can burst and produce EBs, represented by (0, 0, B(t), -1).This final transition does not explicitly represent extrusions, however the parameters that govern the function of extracellular C. trachomatis are allowed to vary over ranges that could include this form of C. trachomatis.

Simulating the model

We simulate the model in continuous time, where time is measured in minutes. We use a grid of initial conditions for X{C1,t=0}=x0 (from 1 to 10,001 in steps of 100, with 10 simulations at each value) and stage of the menstrual cycle (from 0 to 43,200 minutes in steps of 1800, with 10 simulations at each value) for a total of 252, 500 simulations, and assume that X{C2,t=0}=Y{C1,t=0}=Y{C2,t=0}=0. The longest simulation was therefore 43, 200 minutes long. A simulation either ended with material ascended, 0 bacterial load or with some infection present in the epithelium but not in the cervical canal. Events occur according to a Poisson process, with rate parameter λt being the sum of all rate parameters as described in the process scheme above. Fig 2 describes the transitions between states.

Fig 2. Flow diagram of the model.

Fig 2

The figure outlines each component of the model that are incorporated in the analysis. Extracellular chlamydia can form inclusions to created new infected cells, and infected cells can burst to create new extracellular chlamydia. Both extracellular chlamydia and infected cells can be removed by the immune system, and be migrated to the cervical canal via the neutrophil response. In the cervical canal, infected cells can burst to create new chlamydia, but not vice versa. Extracellular Chlamydia and infected cells in the cervical canal be removed via peristalsis. The parameters of each component from the model are drawn from distributions that represent host and pathogen specific factors. The impact of each factor is represented as the proportion of simulations where the infection ascended for each parameter in the model in the following figures, out of a total of 252,500 simulations that were run.

The parameters γ1 and γ2 that govern the immune response are made up of two components, one representing the innate immune system and one representing the adaptive immune system. The adaptive immune response is assumed to operate once a certain threshold level of each infectious unit is achieved and is zero otherwise. These two thresholds (one for EBs, one for infectious cells), are drawn from a negative binomial distribution, with mean 5000 for EBs and 150 for infected cells. The shape parameter for each threshold is drawn from a Beta(1,1) distribution. It is assumed that the immune system response for extracellular bacteria is independent to the response for infected cells. The immune portion of the model is as follows

γ1=γ1,innate+γ1,adaptive
γ2=γ2,innate+γ2,adaptive
γ1,innate,γ2,innateGamma(1,100)
γ1,adaptive{0ifXC1τ1,Gamma(1,100)ifXC1>τ1}
γ2,adaptive{0ifYC1τ2,Gamma(1,100)ifYC1>τ2}
τ1NegBinom(5000,σ1)
τ2NegBinom(150,σ2)
σ1,σ2Beta(1,1)

A consideration for the model was the unique nature of chlamydial growth inside an intracellular inclusion vacuole where the organism replicates in multitudes, and the release of the infectious particles in bursts (by extrusion or lysis). The rate of inclusion developments and bursts are denoted by κ1 and κ2. The burst and inclusion sizes are drawn from a negative binomial with means 350 and 10 respectively, where the shape parameter comes from a Beta(2,2) distribution. The chlamydial inclusion and burst portion of the model can be represented as follows

κ1,κ2Gamma(1,100)
BNegBinom(350,σ3)
INegBinom(10,σ4)
σ3,σ4Beta(2,2)

The rate of migration of infectious material is denoted as α, which assumes that the rate of migration is the same for both EBs and infected cells (i.e. representing cells displaced by the neutrophil response as outlined in the introduction). The number of EBs and cells being migrated due to the neutrophil response is also drawn from a negative binomial, with mean 100 and 10 respectively. The shape parameter for this random variable is drawn from a Beta(1,1) distribution. All shape parameters in the model act as hyperparameters for the uncertainties on the model parameters. They are rarely observed in the literature, and so they are drawn from weakly informative distributions about the exact parameter value. This addition of uncertainty makes the model results less sensitive to specific choices of parameter values.

αGamma(1,100)
M1NegBinom(100,σ5)
M2NegBinom(10,σ6)
σ5,σ6Beta(1,1)

The parameter γ3(t) represents the removal rate of material in the cervical canal at time t. It is modelled as a fixed component and a function that represents variation due to the effect of the menstrual cycle on peristalsis. This assumes that changes in peristalsis occur continuously across the menstrual cycle, and that the menstrual cycle lasts for 30 days. 30 days was arbitrarily assigned, although the model parameters allow for a broad range of variability given the 21–35 day range in the population. The period and phase shift of the sine function are based on the number of minutes in 30 days, and the range is restricted to the interval [0, 1]. Peristaltic movement is represented as follows

γ3(t)=γ3,fixed+0.5sin(π(t10800)21600)+0.5
γ3,fixedGamma(1,1)

The inclusion of probability distributions over the parameters governing the model can be thought of as including uncertainty of host and pathogen specific factors that are not otherwise explicitly modelled. Ascension is defined as having occurred within a simulation, if the population of extracellular C.trachomatis and infected cells, XC2,YC2 is greater than zero when the simulation time finishes. We then summarise the relationship between parameter values of the process, and the proportion of simulations where ascension occurred. Relationships are summarised graphically in the results section using cubic splines.

Results

Modelling permits variation in ascension dynamics

Our modelling abstracts the ascension of C. trachomatis into a set of stochastic dynamics, that allows us to elucidate the moderating factors that might determine whether or not an infection ascends into the upper reproductive tract in women.

As outlined in the methods the factors include extracellular bacteria in the cervical epithelium infect cells which later burst and produce new amounts of bacteria. Immune responses, and in particular the presence of neutrophils, which eject material into the cervical lumen, and uterine peristalsis and the direction. Fig 3 indicates the factors that potentially determine chlamydial ascension. We evaluated three realizations of the same stochastic process with distinct parameter values, distinct initial conditions for infectious load and the same initial conditions for time until cervico-fundal peristaltic contractions and the initial amounts of infected cells and ejected materials to show the major outcomes of the model (A, B, C, refer to the same plots in the figure) indicating the proportions of ascensions influenced by each set of parameters. In scenario A, the input is a high infectious load. In this scenario the infection grows rapidly over time, however insufficient material is ejected from the epithelium and the infection will not ascend (as indicated by the lack of ejected EBs in pale blue in Fig 3A). In scenario B, an output of the model where the input was a low infectious load, the infection is ejected at two distinct time points. However, this leaves insufficient material in the epithelium for the infection to replicate, and so the infection dies out there. Since the infection cannot replicate in the cervical canal, it to dies out well before peristalsis in the upwards direction begins. In the final example, scenario C, the infection is initiated with an even higher infectious load, and in this output from the model the infection survived in the epithelium whilst sufficient amounts of material are ejected (pale blue) for the infection to be present at the point where material can be transported into the upper genital tract.

Fig 3. Graphical representation of the counts for each status of elementary bodies and cells in the model under three distinct scenarios over time.

Fig 3

The figure shows the outputs of simulated sample paths of the model where factors have been modified. Each figure is a demonstration showing selected representations from the 252, 500 simulations that were conducted. (A) An example output from the model that starter with a load in the range of 801 EBs. (B) An example output of the model starting with a low initial load of 501 EBs. (C) An output that commended with a higher load than A and B of 2201 EBs. Each figure shows a graphical representation of count of each cell/chlamydia form represented on the y axis with the actual counts of Chlamydia trachomatis in the different forms indicated by the coloured lines (see figure legend bottom right), and time in minutes (x axis).

Using the model we can examine the role of both burst rates (release of infectious C. trachomatis from cells) and inclusion formation rate (or our measure of establishing new inclusion vacuoles in new cells). This is based on the assumption that an increase in the frequency of bursts, would increase the number of new bacteria circulating in the epithelium. This is somewhat dependent on infectious dose, as higher infecting doses would have an increased frequency of bursts, but this factor reflects the infection across the course of time more generally. Increasing burst frequency does not appear to independently moderate the chances of ascension (Fig 4A). However, increasing the rate at which extracellular bacteria infect target cells does appear to increase the chances of ascension (Fig 4B). The chances of ascension when this rate was set at 0.001 infected cells per minute was estimated at 15.3%, 34.6% when the rate was 0.005 and 55.1 for a rate of 0.05.

Fig 4.

Fig 4

Graphical representation of the proportion of ascension events in the simulations, as influenced by burst rate (A) and new cell infection rate (B).. (A) The relationship between burst rate (in cells per minute) and the simulated chances of ascension. (B) The relationship between new cell infection rate (cells per minute). The y axis shows the proportion of simulations where infections ascended (out of 252, 500 simulations conducted), and x axis shows the different parameters values of burst rate and new cell infection rate). Each dot represents simulations at a particular parameter value. These are simulated over a range of infectious loads (10 simulations at each value of infectious load from 1 to 10001 in steps of 100. The blue line represents a loess fit of ascension proportion against each parameter value, where shading is the 95% confidence interval of the fit.

Next, we examined simulations of the model to assess how frequently ascension occurs and the amount of bacteria that ascend. As Fig 5 demonstrates, even in infections where the bacteria ascend, there is a long tail in the distribution of how much bacteria will reach the upper genital tract. In our simulations, the median number of bacteria that ascended per infection was 0, with an interquartile range of 0 to 127. The top 25% of infections had between 127 and 59,090 bacteria ascended. This exercise gives an estimate of 36% of infections that ascend, but only 9% where more than 1000 bacteria managed to ascend, and 0.1% where more than 10,000 bacteria ascended.

Fig 5. Histogram of the proportion of simulations leading to ascension of bacteria, and the amount of bacteria predicted by the model to ascend.

Fig 5

The amount of bacteria predicted to ascend (x axis) and the proportions of each simulation that resulted in ascension (y axis) from 252, 500 simulations of the model. These are simulated over a range of infectious loads (10 simulations at each value of infectious load from 1 to 10001 in steps of 100.

Modelling indicates a role for initial infectious load and timing relative to the menstrual cycle for ascension

Overall, initial infectious load was influential on ascension events. Specifically, in this model we found initial loads in the range of 1000–3500 were most likely to ascend, with an apparent decrease in ascension found for higher loads (Fig 6A). The timing of initial infection relative to the onset of peristaltic contractions in the cervico-fundal direction (which is moderated by the menstrual cycle) had a much more marked impact on the simulated chances of ascension (Fig 6B). For example, infections that were initiated 30 hours prior to the onset of upwards peristaltic movement had a 7.8% of ascension, whereas infections initiated 10 days or more prior had a 42% of ascension. The relationship between infectious load and timing was also found to be critical in influencing ascension. Infections with smaller infectious loads experience linearly decreasing chances of ascension as the menstrual cycle progresses, so an infection that occurs later in the cycle may have reduced chances of ascending. However, the opposite applies to high infectious loads, where infections have a higher chance of ascending as the menstrual cycle progresses closer to peristaltic movement in the cervico-fundal direction (Fig 6C). Although a high initial load of 10001 had a broadly constant chance of ascension between 39–43%, for infections that were initiated 22 or more days prior to upwards peristaltic movement.

Fig 6.

Fig 6

Graphical summary of the proportions of simulations where ascension occurred and role of load (A), peristalsis (B), and both (C). (A) Simulations analysing the impact of infectious load (the count of initial bacteria) on the the chances of ascension. (B) The time (in minutes) prior to the onset of peristaltic contractions in the cervico-fundal direction and chances of ascension. (C) The relationship between infectious load, timing of infection with respect to peristaltic contractions, and the chances of ascension. Each figure shows the proportion of simulations from the model where the infection ascended (proportion of representations from 252, 500 simulations) on the y axis, where the x axis represents the factor being modified (A. infectious load, B. peristalsis, C. peristalsis and grouped by infectious load). These are simulated over a range of infectious loads (10 simulations at each value of infectious load from 1 to 10001 in steps of 100. The blue lines represent a loess regression against the proportion of simulations resulting in ascension, and the shaded regions are 95% confidence intervals of the regression. Dots represent simulations at a particular parameter value.

Ascension chances are dependent on the neutrophil response in this model

Our simulation experiments show that the chances of ascension are broadly independent of the immune systems response (defined as overall scale of response, Fig 7), indicated by death rate of infectious material (extracellular EBs and infected cells) and moderated by the global immune response (separated into innate and adaptive systems). It is important to note that these phenomena represent the relative strength and weaknesses of the overall immune system and its responses between hosts. The model predicts that increasing or decreasing the strength of the host immune response, that determines the removal of EBs and infected cells, would have no impact on the chances of a particular infection ascending. The outcomes of the model under these parameters was that death of infected cells (Fig 7B and 7D) at a higher rate (rather than EBs, Fig 7A and 7C) was more likely to reduce the proportion of infections that ascended in the simulations (although the outcomes of the model at high death rates were highly variable 0–100% of ascensions).

Fig 7. Graphical representation of the impact of the immune response and subsequent chlamydial death rate on the proportion of simulations that result in ascension.

Fig 7

The proportion of simulations where the infection ascends was computed (total 252,500 simulations represented in each figure). Each figure shows the proportion of simulations where the infection ascended on the y axis and on the x axis the death rate of EBs and infected cells due to different components of the immune system (represented as broad scales of response). (A) Impact of EB death rate due to the innate immune system on the proportion ascending, (B) Impact of infected cells death rate due to the innate immune system on the proportion ascending, (C) Impact of EB death rate due to the adaptive immune system on the proportion ascending, and (D) Impact of infected cells death rate due to the adaptive immune system on the proportion ascending. These are simulated over a range of infectious loads (10 simulations at each value of infectious load from 1 to 10001 in steps of 100.The solid blue line indicates a loess fit to the proportion of simulations the ascended and the shaded area represents 95% Confidence Intervals of the loess regression. Dots represent simulations at a particular parameter value from a total of 252, 500.

Infections that instigate higher neutrophil responses are more likely to be one that ascend (Fig 8). The simulated probability of ascension was 15.8% for a rate of 0.001 (per minute), and 42.5% for a simulated rate of 0.01. The exact nature of this relationship depends on the stage of the menstrual cycle in which infection occurs. It is an assumption of the model that the neutrophil response and other features of the innate and adaptive immune response are related by their density-dependence. That is, the ejection rate of cells due to the neutrophil response is higher when the removal rate of infected cells due to the innate and adaptive response is higher, as both respond to the overall density of infected cells.

Fig 8. Graphical representation of the proportion of infections that ascend in the simulations from the model and the role of the neutrophil response.

Fig 8

The figure shows the proportions of simulations (total of 252, 200 conducted for each instance) where infection was predicted to ascend (y axis). The ejection rate (movement to the cervix from the epithelium) of infected cells related to the neutrophil response (x axis). (A) Ascension and the ejection rate due to the neutrophil response. (B) Impact of initial infectious load (pink represents a low infectious load of 101, green a moderate infectious load of 2501, and blue 10,001). (C) Time of infection relative to the menstrual cycle (follicular phase represented by pink, and ovulatory phase represented by blue). These are simulated over a range of infectious loads (10 simulations at each value of infectious load from 1 to 10001 in steps of 100. In each graph the solid blue line indicates a loess fit to proportion of simulations resulting in ascension, where the shaded area shows is the 95% confidence interval. Each dots are represents simulations at a particular parameter value, from a total of 252,500.

Discussion

In this study we have applied a modelling approach to evaluate factors that influence chlamydial ascension in women. The impact of infectious burden on the likelihood of ascension shown as realisations in several iterations of the model presented here is not inconsistent with what might be expected from existing biological data in mouse and humans. It has been proposed that a strong adaptive immune system response may be sufficient to clear the infection from the cervix before ascension can occur [24]. Our modelling results indicate that ascension occurs independently of the strength of the immune system response, suggesting that the progression to pathological outcomes in the upper reproductive tract is not so straightforward. However, the presence of a neutrophil response has been previously associated with C. trachomatis and the development of pathology. There are a variety of studies that support the presence of neutrophils with C. trachomatis and endometritis [25, 26]. Implicating the neutrophil responses in the movement of the pathogen, in spite of its role in controlling infections, and thus the findings here from our modelling are consistent with the literature on neutrophils. Our model assumes that the neutrophil response is critical in epithelium to the cervical canal, and so the neutrophil response plays a different role in modulating ascension to that observed from the global innate immune system, in regards to the relationship between high and low immune response and ascension [8]. It is not clear from the available literature if the neutrophil response varies independently between hosts, or if it occurs as a function of the amount of C. trachomatis present at a particular site in the epithelium (or both). From the perspective of the pathogen, one could view the evolution of C. trachomatis alongside the neutrophil response as a process that has selected for these adaptations to exploit this natural defence mechanism to ensure pathogen survival. The evidence we provide here suggests that an influx of neutrophils may be a useful predictor of an ascending infection.

This interaction between the host’s defence mechanism and the infection must be time-dependent for an infection to successfully ascend according to the outcomes shown here. As migration from the initial site of infection during the earlier phases of the menstrual cycle will more likely spread the infection too thin, with insufficient material left in the epithelium in order to ensure to short term survival of the infection and to ensure adequate infectious material for successful transmission to new hosts. Our simulations indicate that both the infecting load and the menstrual cycle moderate ascension, and that this moderation occurs in a dynamic and dependent way. There is limited biological data to compare with the proportions of infections that ascend that we have predicted here in the model. Ascension of chlamydia is a necessary, but not sufficient condition for pathology (such as PID) to develop, and we know that PID occurs in approximately 9.5% of chlamydial infected women [1]. In a majority of our simulations where ascension did occur, the amount of material that ascended was relatively small (although 9% of ascensions in one model had greater than 1000 organisms, Fig 5). A case-control study of women with positive (cases) and negative (controls) tests for chlamydia, gonorrhoea or bacterial vaginosis, found the women in the follicular phase of their menstrual cycle had an adjusted odds ratio of 4.5 (95% CI (1.6–12.4) of experiencing upper genital tract infection [27]. Although the timing of biopsy in this clinical evidence is not necessarily equivalent to the timing of ascension, this study supports the findings we present that menstrual cycle moderates ascension through peristalsis. Our modelling finds that infections that are initiated in this stage of the menstrual cycle are least at risk of ascending.

A key assumption of this modelling exercise is that uterine peristalsis changes continuously with the menstrual cycle. For an infection to ascend, it requires exact timing with the menstrual cycle in order to utilise the peristaltic activity of the uterus. However, women with dysfunctions of the peristaltic mechanisms, such as hyperperistalsis, may experience peristaltic activity at three times the rate of women without these dysfunctions [28]. Further, there is some evidence that women with high uterine peristalsis have reduced pregnancy rates due to the presence of intramural fibroids [29]. Although speculation, it is plausible the women with increased peristaltic activity due to uterine fibroids would be at increased risk of ascending infections.

The limitations of this work should be noted. This exercise characterises the process through simulated realisations of the model, and it is not calibrated or fit against biological datasets. Additionally, as with all modelling, our results rest on a set of assumptions that can potentially be modified to realise different outcomes. This cannot be avoided, although we have been as rigorous as possible in simulating over a broad range of parameter values and including stochastic terms to ensure the dynamic nature of the observations is encompassed. Unlike previous mathematical models of chlamydia [13, 18, 22, 23], the model presented in this study incorporates stochastic elements that samples across a broad range of parameter values, which influences realised outcomes of the model and provides some robustness to the results presented [21]. Also, we do not continue the simulations beyond the point of upwards peristalsis within the stage of the cycle, meaning the longer term implications for the longer time course of the infection have not been considered in the model. The results may be extrapolated to determine the chances in subsequent cycles after the initial cycle, although a model specifically developed to answer the likelihood of ascension in subsequent months may be a more appropriate approach for longer range estimates. A significant component of chlamydial function not included in the model is the differing strategies that C. trachomatis uses to exit the cell. The mechanisms that govern lysis and extrusion cellular release pathways are distinct and may vary in the rate at which they occur and the amount of C. trachomatis released from the cell [20]. Extrusions of chlamydial inclusions have the ability to utilise macrophages as intracellular survival niches [30]. The pathogen may then be able to exploit macrophages as a vehicle of dissemination within a host. The macrophage response has implications for other bacterial pathogens, in particular Neisseria gonorrhoeae, which has the ability to inhibit apoptosis and use macrophages as a replicative survival niche [31, 32].

In conclusion, we have proposed a process for the ascension of chlamydial infections, by considering the available clinical evidence and experimental observations of the pathogen and combining these observations into a stochastic model that allows us to understand the influential factors of ascension. The dynamics of the process are complex, nonlinear, and stochastic, so we model this in order to reason about the moderating factors. From our simulation results, we propose that cervical neutrophil responses and infectious burden could be useful as early indicators of the likelihood of pathology. This would need to be validated with further examination of neutrophil levels as predictive markers for pathology development of women who have recent exposure to C. trachomatis. Further we propose that the model could be more broadly applied to other STI to identify relevant factors for ascension and pathology risk in the cases of those pathogens.

Supporting information

S1 Fig. A histogram of the amount of ascended bacteria under different distributional assumptions.

Each histogram represents 12,625 simulations from the model, where the underlying distribution for the rate parameters has been selected from an exponential distribution, a gamma distribution and a log-normal distribution. All distributions have identical means of 1/100.

(TIF)

S1 Text. Provides information on the Parametrisation of key distributions.

(DOCX)

Data Availability

All relevant data are within the manuscript and its Supporting Information files.

Funding Statement

This work is supported by an Australian Government Research Training Program (RTP) scholarship awarded to TC (https://www.dese.gov.au/research-block-grants/research-training-program). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

References

  • 1.Oakeshott P, Kerry S, Aghaizu A, Atherton H, Hay S, Taylor-Robinson D, et al. Randomised controlled trial of screening for Chlamydia trachomatis to prevent pelvic inflammatory disease: the POPI (prevention of pelvic infection) trial. BMJ. 2010;340. doi: 10.1136/bmj.c1642 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Low N, Egger M, Sterne JAC, Harbord RM, Ibrahim F, Lindblom B, et al. Incidence of severe reproductive tract complications associated with diagnosed genital chlamydial infection: the Uppsala Women’s Cohort Study. Sex Transm Infect. 2006;82(3):212–8. doi: 10.1136/sti.2005.017186 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.Westrom L, Joesoef R, Reynolds G, Hagdu A, Thompson SE. Pelvic Inflammatory Disease and Fertility. Sexually Transmitted Diseases. 1992;19(4):185–92. [PubMed] [Google Scholar]
  • 4.Davies B, Turner KME, Frølund M, Ward H, May MT, Rasmussen S, et al. Risk of reproductive complications following chlamydia testing: a population-based retrospective cohort study in Denmark. The Lancet Infectious Diseases. 2016;16(9):1057–64. doi: 10.1016/S1473-3099(16)30092-5 [DOI] [PubMed] [Google Scholar]
  • 5.Stacey C, Munday P, Thomas B, Gilchrist C, Taylor-Robinson D, Beard R. Chlamydia trachomatis in the fallopian tubes of women without laparoscopic evidence of salpingitis. International Journal of Gynecology & Obstetrics. 1991;35(3):287. [DOI] [PubMed] [Google Scholar]
  • 6.Menon S, Timms P, Allan JA, Alexander K, Rombauts L, Horner P, et al. Human and Pathogen Factors Associated with Chlamydia trachomatis Related Infertility in Women. Clinical Microbiology Reviews. 2015;28(4):969–85. doi: 10.1128/CMR.00035-15 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Haggerty CL, Gottlieb SL, Taylor BD, Low N, Xu F, Ness RB. Risk of Sequelae after Chlamydia trachomatis Genital Infection in Women. The Journal of Infectious Diseases. 2010;201:S134–S55. doi: 10.1086/652395 [DOI] [PubMed] [Google Scholar]
  • 8.Maxion HK, Liu W, Chang M-H, Kelly KA. The Infecting Dose of Chlamydia muridarum Modulates the Innate Immune Response and Ascending Infection. Infection and Immunity. 2004;72(11):6330–40. doi: 10.1128/IAI.72.11.6330-6340.2004 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Vodstrcil LA, McIver R, Huston WM, Tabrizi SN, Timms P, Hocking JS. The Epidemiology of Chlamydia trachomatis Organism Load During Genital Infection: A Systematic Review. The Journal of Infectious Diseases. 2014;211(10):1628–45. doi: 10.1093/infdis/jiu670 [DOI] [PubMed] [Google Scholar]
  • 10.Carey AJ, Cunningham KA, Hafner LM, Timms P, Beagley KW. Effects of inoculating dose on the kinetics of Chlamydia muridarum genital infection in female mice. Immunology and Cell Biology. 2009;87(4):337–43. doi: 10.1038/icb.2009.3 ; 9350790. [DOI] [PubMed] [Google Scholar]
  • 11.Geisler WM, Suchland RJ, Whittington WLH, Stamm WE. Quantitative Culture of Chlamydia trachomatis: Relationship of Inclusion-Forming Units Produced in Culture to Clinical Manifestations and Acute Inflammation in Urogenital Disease. The Journal of Infectious Diseases. 2001;184(10):1350–4. doi: 10.1086/323998 [DOI] [PubMed] [Google Scholar]
  • 12.Abdelrahman YM, Belland RJ. The chlamydial developmental cycle. FEMS Microbiol Rev. 2005;29(5):949–59. Epub 2005/07/27. doi: 10.1016/j.femsre.2005.03.002 . [DOI] [PubMed] [Google Scholar]
  • 13.Mallet DG, Heymer K-J, Rank RG, Wilson DP. Chlamydial infection and spatial ascension of the female genital tract: a novel hybrid cellular automata and continuum mathematical model. FEMS Immunology And Medical Microbiology. 2009;57(2):173–82. doi: 10.1111/j.1574-695X.2009.00596.x . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Mallet DG, Bagher-Oskouei M, Farr AC, Simpson DP, Sutton K-J. A Mathematical Model of Chlamydial Infection Incorporating Movement of Chlamydial Particles. Bulletin of Mathematical Biology. 2013;75(11):2257–70. doi: 10.1007/s11538-013-9891-9 [DOI] [PubMed] [Google Scholar]
  • 15.Rank RG, Whittimore J, Bowlin AK, Dessus-Babus S, Wyrick PB. Chlamydiae and polymorphonuclear leukocytes: unlikely allies in the spread of chlamydial infection. FEMS Immunology And Medical Microbiology. 2008;54(1):104–13. doi: 10.1111/j.1574-695X.2008.00459.x . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Barteneva N, Theodor I, Peterson EM, de la Maza LM. Role of neutrophils in controlling early stages of a Chlamydia trachomatis infection. Infection and Immunity. 1996;64(11):4830–3. doi: 10.1128/iai.64.11.4830-4833.1996 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Kunz G, Leyendecker G. Uterine peristaltic activity during the menstrual cycle: characterization, regulation, function and dysfunction. Reproductive biomedicine online. 2002;4Suppl 3:5–9. doi: 10.1016/s1472-6483(12)60108-4 [DOI] [PubMed] [Google Scholar]
  • 18.Wilson DP. Mathematical modelling of Chlamydia. ANZIAM J. 2004;45:C201—C14. PubMed Central PMCID: PMC2004. doi: 10.1016/j.jtbi.2003.09.010 [DOI] [PubMed] [Google Scholar]
  • 19.Pearson JE, Krapivsky P, Perelson AS. Stochastic Theory of Early Viral Infection: Continuous versus Burst Production of Virions. PLoS Computational Biology. 2011;7(2):e1001058. doi: 10.1371/journal.pcbi.1001058 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Hybiske K, Stephens RS. Mechanisms of host cell exit by the intracellular bacterium Chlamydia. Proceedings of the National Academy of Sciences. 2007;104(27):11430–5. doi: 10.1073/pnas.0703218104 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Callan T, Woodcock S. Stochastic Modelling of Chlamydial Infections. ANZIAM J. 2020;61:89–103. 10.21914/anziamj.v61i0.15159. [DOI] [Google Scholar]
  • 22.Wilson DP, McElwain DLS. A model of neutralization of Chlamydia trachomatis based on antibody and host cell aggregation on the elementary body surface. Journal of Theoretical Biology. 2004;226(3):321–30. doi: 10.1016/j.jtbi.2003.09.010 [DOI] [PubMed] [Google Scholar]
  • 23.Sharomi O, Gumel AB. Mathematical study of in-host dynamics of Chlamydia trachomatis. IMA Journal of Applied Mathematics. 2012;77(2):109–39. doi: 10.1093/imamat/hxq057 . [DOI] [Google Scholar]
  • 24.Darville T, Hiltke TJ. Pathogenesis of genital tract disease due to Chlamydia trachomatis. The Journal of infectious diseases. 2010;201 Suppl 2(Suppl 2):S114–S25. doi: 10.1086/652397 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Yudin MH, Hillier SL, Wiesenfeld HC, Krohn MA, Amortegui AA, Sweet RL. Vaginal polymorphonuclear leukocytes and bacterial vaginosis as markers for histologic endometritis among women without symptoms of pelvic inflammatory disease. American Journal of Obstetrics and Gynecology. 2003;188(2):318–23. doi: 10.1067/mob.2003.105 [DOI] [PubMed] [Google Scholar]
  • 26.Wiesenfeld HC, Heine RP, Krohn MA, Hillier SL, Amortegui AA, Nicolazzo M, et al. Association between Elevated Neutrophil Defensin Levels and Endometritis. The Journal of Infectious Diseases. 2002;186(6):792–7. doi: 10.1086/342417 [DOI] [PubMed] [Google Scholar]
  • 27.Korn AP, Hessol NA, Padian NS, Bolan GA, Donegan E, Landers DV, et al. Risk factors for plasma cell endometritis among women with cervical Neisseria gonorrhoeae, cervical Chlamydia trachomatis, or bacterial vaginosis. American Journal of Obstetrics and Gynecology. 1998;178(5):987–90. doi: 10.1016/s0002-9378(98)70536-8 [DOI] [PubMed] [Google Scholar]
  • 28.Leyendecker G, Kunz G, Wildt L, Beil D, Deininger H. Uterine peristalsis and dysperistalsis as dysfunction of the mechanism of rapid sperm transport in patients with endometriosis and infertility. Human reproduction (Oxford, England). 1996;11:1542–51. [DOI] [PubMed] [Google Scholar]
  • 29.Yoshino O, Hayashi T, Osuga Y, Orisaka M, Asada H, Okuda S, et al. Decreased pregnancy rate is linked to abnormal uterine peristalsis caused by intramural fibroids. Human Reproduction. 2010;25(10):2475–9. doi: 10.1093/humrep/deq222 [DOI] [PubMed] [Google Scholar]
  • 30.Zuck M, Ellis T, Venida A, Hybiske K. Extrusions are phagocytosed and promote Chlamydia survival within macrophages. Cell Microbiol. 2017;19(4). Epub 2016/10/16. doi: 10.1111/cmi.12683. [DOI] [PubMed] [Google Scholar]
  • 31.Château A, Seifert HS. Neisseria gonorrhoeae survives within and modulates apoptosis and inflammatory cytokine production of human macrophages. Cellular microbiology. 2016;18(4):546–60. Epub 2015/10/26. doi: 10.1111/cmi.12529 . [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Escobar A, Rodas PI, Acuña-Castillo C. Macrophage–Neisseria gonorrhoeae Interactions: A Better Understanding of Pathogen Mechanisms of Immunomodulation. Frontiers in Immunology. 2018;9(3044). doi: 10.3389/fimmu.2018.03044 [DOI] [PMC free article] [PubMed] [Google Scholar]
PLoS Comput Biol. doi: 10.1371/journal.pcbi.1009365.r001

Decision Letter 0

Rob J De Boer, Janneke Heijne

18 Apr 2021

Dear Dr. Huston,

Thank you very much for submitting your manuscript "Ascension of Chlamydia is moderated by uterine peristalsis and the neutrophil response to infection" for consideration at PLOS Computational Biology.

As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. In light of the reviews (below this email), we would like to invite the resubmission of a significantly-revised version that takes into account the reviewers' comments.

We cannot make any decision about publication until we have seen the revised manuscript and your response to the reviewers' comments. Your revised manuscript is also likely to be sent to reviewers for further evaluation.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to the review comments and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out.

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Please prepare and submit your revised manuscript within 60 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email. Please note that revised manuscripts received after the 60-day due date may require evaluation and peer review similar to newly submitted manuscripts.

Thank you again for your submission. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Janneke Heijne, Ph.D.

Guest Editor

PLOS Computational Biology

Rob De Boer

Deputy Editor

PLOS Computational Biology

***********************

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: This is an interesting and well written paper on several factors that might moderate ascension of Chlamydia trachomatis infections to the upper genital tract in women. Results of the study indicate that infectious load, menstrual cycle timing, and the neutrophil response are important factors in the ascension of chlamydia. Results might increase insight in the pathology of chlamydia infections and factors might enable specific testing for at-risk of high risk women, or aid the development of interventions at timing of infection. In light of the current paradigm of chlamydia control and the question “what should we do with chlamydia control?” this paper is relevant and contributes to finding new ways of identifying high risk women.

Specific comments/questions include:

1. Line 67: In the introduction, several factors were mentioned to moderate in the ascension of chlamydia (menstrual cycle, stage of infection, immune status, genotype factors (host and pathogen) and infectious load). But not all were elucidated further in the introduction (for example genotype factors), while all factors were included in the model.

2. Line 114: “The PMN response was observed to result in detached superficial epithelia from the mucosa, including infected cells and elementary bodies that remained healthy and intact during the process. It was suggested by Rank et al. that this response was a defensive mechanism from the perspective of the host organism in that it allows for infected cells that have been ejected from the epithelium to be cleared from the infection site. Further, it was proposed that from the perspective of the Chlamydia, this process allowed for movement away from infected sites where there is a lack of susceptible uninfected cells, transporting to new infection sites via fluid dynamics or tissue movement.” Wouldn’t you expect that, primarily the fluid dynamics or vaginal secretion, will descend the infected cells rather than ascend? How does that interreact?

3. Line 144: “Elucidating the processes involved in chlamydial ascension will provide a better understanding of the pathogenesis of Chlamydia associated PID and infertility. In turn, the moderating factors could enable more specific testing for at-risk women, or development of other interventions when infections are diagnosed.” Although I agree that elucidating processes around the ascension of chlamydia is relevant, specific testing for at-risk women concerning the menstrual cycle requires the need of timing of infection. Even more so the timing of ascending of the bacteria. How long might an infection reside in the lower genital tract before ascending?

4. Line 182: Is it correct that you assume that ejected infected cells contain viable RBs that will differentiate back in EBs? In other words that neutrophils were unable to inactivate chlamydia?

5. Line 348: “However, increasing the rate at which extracellular bacteria infect target cells does appear to increase the chances of ascension. This points towards the increased utility of infected cells to the infection, as they influence migration and will produce greater amounts of bacteria in the future.” How would the rate at which EB infect target cells be increased? Can you elaborate more on how this points towards the increased utility of infected cells?

6. Line 372: “The relationship between infectious load and the menstrual cycle further complicates matters. Infections with smaller infectious loads experience linearly decreasing chances of ascension as the menstrual cycle progresses, so an infection that occurs later in the cycle may have reduced chances of ascending. However, the opposite applies to high infectious loads, where infections have a higher chance of ascending as the menstrual cycle progresses closer to peristaltic movement in the cervico-fundal direction.” It seems that the chance of an ascending infection increases when you have either low initial loads early in the menstrual cycle or high loads later in the menstrual cycle. Are these chances comparable? Or is the chance of ascending with higher loads but later in the menstrual cycles still significantly lower compared to low initial loads early in the menstrual cycle. The conclusion in the abstract would suggest the latter.

7. Furthermore the interaction between infectious load and menstrual cycle: Is that based on the menstrual cycle during time of initial infection? “Infections with smaller infectious loads experience linearly decreasing chances of ascension as the menstrual cycle progresses”, but if the infection is not cleared it might produce enough material so that in the following menstrual cycle there would be enough material that might cause a new infection in the upper genital tract? For example after one year after initial infection, without treatment, only 50% of women have cleared the infection. Could you elaborate on that?

8. I’m am somewhat confused about how the neutrophil response relates to high and low initial infectious loads. In the introduction it was said that in case of high infection loads the immune response was sufficient to prevent ascension but not for lower loads. But in the results it was found that infections with high neutrophil responses were more likely to be one that ascend. Could you elaborate on that?

9. Line 411: You propose to investigate the strict set of markers to investigate in a cohort study to examine development of upper genital tract pathology. How would you set up such a cohort?

10. Line 477: A study from Korn concluded that he proliferative phase of the menstrual cycle seems to be the primary risk factor for ascending infection by organisms associated with pelvic inflammatory disease. From the results of the study I don’t think that it can be concluded that timing of biopsy is equal to timing of ascension. The ascension might have happened days or weeks before and might differ between hosts.

Reviewer #2: Manuscript Number: PCOMPBIOL-D-20-02253

Title: Ascension of chlamydia is moderated by uterine peristalsis and the neutrophil response to infection

In this study, the authors constructed a stochastic model that describes the dynamics between extracellular chlamydial elementary bodies and infected cells containing chlamydial reticulate bodies in the epithelium and the probability that these ascend to the cervical canal. It is investigated how factors such as the infectious load, the menstrual cycle timing, and the neutrophil response could affect chlamydial ascension in women.

This is a very interesting study. Although it is clear that ascension can occur, it is unclear which factors facilitate or hinder ascension. The authors have developed a simple model that captures the main elements of this process, thus illustrating the role of some important factors, such as the infectious load or the phase of the menstrual cycle.

However, the study needs quite some improvement. The notation in the mathematical formulas is inconsistent and unclear and methods need some clarifications. English language needs improvement. References have to be added throughout the manuscript to support the arguments. The discussion contains too many repetitions, but does not cover important items, such as limitations and discussion/comparisons with similar studies. These points are explained in detail below.

My main consideration about the study is that, as the authors mention in the discussion (page 14), there are hardly any data to compare with model results for some level of validation. That makes the study kind of speculative or hypothetical. Also, the authors provide no evidence/reference to support their assumptions for the distributions of the parameters (e.g. Gamma, Beta, Negative Binomial and their means/shape parameters). If two or three of these parameters have a different distribution or the shape parameter is half of what the authors assumed, the results could be quite different. Although this is inherent for all models (input quality determines output quality), modelling studies nowadays provide extensive support for the model parameters (from earlier studies or directly estimated from data) AND model validation or fitting to data. That provides some level of confidence in the qualitative conclusions of modelling studies, which here lacks.

Some additional points that could improve the study are listed below.

1. Line 187: In discussion, please explain how the results are affected by the assumption of instantaneous burst as opposed to continuous.

2. Lines 215-223: The formula’s presented here are incomprehensible, especially since the notation in Figure 2 seems to imply that the rate is I*k1 or M1 * YC1 etc. The information in these formula’s is more or less repeated in the paragraphs from line 237 to 315. The authors could reorganize the text by deleting the repetitions and provide all information about each process in the model together (e.g. all formulas, explanations, assumptions, distributions, parameters about the immune response; then those about inclusion and bursts etc).

3. Pages 8-9: Please remove Latex notation and use the same notation for each variable/parameter (e.g. gamma1 or gamma_1 in lines 267-270; or \\gamma and Greek gamma in lines 307,308).

4. Lines 270-271: Gamma(1,00): what is after the comma?

5. Pages 8-9: Please provide some references or explanation for the assumptions about the distributions and the values of the parameters of the distributions used.

6. Lines 311-313: Ascension is defined as a yes/no event, depending on whether ascension occurred “when the simulation time finishes”. Maybe I have missed it, but when does the simulation finishes? How does the % ascending depend on the length of this time? How would the results about the proportion ascending differ with twice as long or half of this time?

7. Legends of Figures 3-8: The legends discuss the results shown in the plots and draw conclusions. This is NOT the purpose of the legends. Please remove all text describing results and conclusions. The legends should explain what is shown in the plots and the scenarios, parameters, or methodology for each specific plot or result shown. Also, please add units where appropriate (e.g. “time” and “load” are measured in what?)

8. Lines 323-332: These are not results of this study; please remove this paragraph.

9. Lines 334-341: Please include reference to figure 3 at the beginning of the paragraph. The reader has to read the whole paragraph to understand where these results are shown. What is scenario A, B, C? do you mean plots A,B,C? What is the difference between the three plots? Are they just 3 realizations (with same parameter distributions and same initial conditions? If not, how do they differ? If they are with same parameters and initial conditions, then please add explicitly something like “plots A, B, C show three realizations of the same stochastic process with same parameter values and initial conditions showing the three major types of the course of the infection: not ascending, ejecting but finally dying out, surviving”.

10. Results: The whole section provides mostly a qualitative description of the results, e.g. this increases when that rates increase etc. Please provide some indicative quantitative results. For example, if the rate is 0.05, then the % ascending is 25%; with a rate of 0.10, the % ascending is 35% etc. Also, please remove conclusions, like “this points towards the increased utility of…”, and place them in the discussion.

11. Legend figure 4: “(A) increasing the rates of burst does not appear to impact the chances of ascension”: Again, this is description of result and drawing conclusions. The legend of this plot should be something like “The proportion ascending with different rates of burst”. Please make similar changes to all legends.

12. Lines 356-358: This text is unclear. Please rephrase.

13. Legend Figure 5: This plot is not a “summary of simulations”. Please use a proper name to describe this kind of figure. Please mention the number of simulations used for this plot and delete all conclusions.

14. Legend Figure 6: The horizontal axis shows the “amount of time since infection”; please add units and change the legend since the phases of the cycle are not shown. The authors could add the phases.

15. Figure 7: Please explain/comment on the fact that the percentage of simulations ascending with high rates varies from zero to 100%! The legend for A reads “Innate immune system impact on EB death rate”, but I think it shows the impact of EB death rate due to innate immune system on % ascending”. The same for the other plots. Please update.

16. Discussion: This section is quite long and contains a lot of repetition from introduction and results. Please remove repetitions. Please add a discussion of limitations of the study (e.g. impact of assumed distributions and parameters of the distributions), as well as comparison with earlier studies on the subject.

**********

Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #2: No: No data or references are given to support distributions and values of model parameters

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

**********

Have all data underlying the figures and results presented in the manuscript been provided?

Large-scale datasets should be made available via a public repository as described in the PLOS Computational Biology data availability policy, and numerical data that underlies graphs or summary statistics should be provided in spreadsheet form as supporting information.

Reviewer #1: Yes

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example in PLOS Biology see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1009365.r003

Decision Letter 1

Rob J De Boer, Janneke Heijne

14 Jul 2021

Dear Dr. Huston,

Thank you very much for submitting your manuscript "Ascension of Chlamydia is moderated by uterine peristalsis and the neutrophil response to infection" for consideration at PLOS Computational Biology. As with all papers reviewed by the journal, your manuscript was reviewed by members of the editorial board and by several independent reviewers. The reviewers appreciated the attention to an important topic. Based on the reviews, we are likely to accept this manuscript for publication, providing that you modify the manuscript according to the review recommendations.

Please prepare and submit your revised manuscript within 30 days. If you anticipate any delay, please let us know the expected resubmission date by replying to this email.

When you are ready to resubmit, please upload the following:

[1] A letter containing a detailed list of your responses to all review comments, and a description of the changes you have made in the manuscript. Please note while forming your response, if your article is accepted, you may have the opportunity to make the peer review history publicly available. The record will include editor decision letters (with reviews) and your responses to reviewer comments. If eligible, we will contact you to opt in or out

[2] Two versions of the revised manuscript: one with either highlights or tracked changes denoting where the text has been changed; the other a clean version (uploaded as the manuscript file).

Important additional instructions are given below your reviewer comments.

Thank you again for your submission to our journal. We hope that our editorial process has been constructive so far, and we welcome your feedback at any time. Please don't hesitate to contact us if you have any questions or comments.

Sincerely,

Janneke Heijne, Ph.D.

Guest Editor

PLOS Computational Biology

Rob De Boer

Deputy Editor

PLOS Computational Biology

***********************

A link appears below if there are any accompanying review attachments. If you believe any reviews to be missing, please contact ploscompbiol@plos.org immediately:

[LINK]

Reviewer's Responses to Questions

Comments to the Authors:

Please note here if the review is uploaded as an attachment.

Reviewer #1: Following the first peer-review round, the authors made significant improvements to the manuscript. Elaborations and explanations have been made and the manuscript is more concise, specifically the discussion section.

Specific comments:

1. Table 1 is an improvement and gives insight in the parameters. The table itself is rather large, which decreases readability. Could you make the table more concise (for example Colom wide modifications).

2. Headings in the result section come across as conclusions, for example line 393 and 413-414.

3. The discussion starts off with a limitation and comparison of the literature on line 443-451; commenting on dysfunctions of the peristaltic mechanisms, this comes out of nowhere. It might be worthwhile to mention it somewhere in the discussion, but please start the discussion focusing on the results of studied factors that influence chlamydial ascension.

4. Line 525 please choose either examining/evaluating.

5. In the conclusion you mentioned you could consider to further examining neutrophil levels as predictive markers for pathology development, but you also propose to that neutrophil levels could be useful as early indicators for pathology likelihood. The way that this is phrased weakens the conclusion. What is it you want to conclude? Could neutrophil levels potentially be useful as early indicators and therefor further examination is needed? Or is it useful even without further examination?

Reviewer #2: PCOMPBIOL-D-20-02253R1

The manuscript is considerably improved and the authors have addressed most of my questions. However, there are some points that need some clarification/improvement:

1. How much time were the simulations carried out to determine whether ascension occurred or not? Did the authors examine/assess whether the % ascending depends on the duration of simulations? I had raised this point in my first review (point 6), but the response of the authors was unclear: they write that the “simulation is stopped when peristalsis causes material to begin ascending”. In some simulations, ascension does not occur, so my question is: how long were these simulations carried out? Did the authors assume that all infections end with either 0 bacterial load or ascension and continued the simulations until one of the two events occurred? In that case, what was the max time needed to reach one of the two endpoints? That helps to understand the time scales. Please add this information and explanation in the main text.

2. A point relating to time: in the author’s response to point 7 of Reviewer 1, the authors state that “an infection in month 2 of 1000 EBs is equivalent to a new infection of 1000 EBs”. However, an infection of 1000 EBs in month X, may become an infection of 2000 EBs (for example) in month Y – and that possibly depends on the time Y-X? Can you explain how that was modelled? If infections in subsequent menstrual cycles are equivalent to new infections, how was the menstrual cycle included in the model?

3. Lines 233-239: “chlamydia” usually refers to the disease itself. Please use here another term instead of chlamydia and, preferably, the same term you use in the previous paragraphs (EB, if I understand it correctly) to avoid confusion.

4. Fig.3: In line 372, it says that the three scenarios A, B, C show realizations of the same stochastic process with distinct parameter values and same initial conditions. In the legend and in the Results section, it is stated that the three scenarios A, B, C, start with different initial load. I would expect that the “initial load” is one of the initial conditions, not a parameter. What exactly is the initial load? Is it the value of one of the model variables at t=0 or one of the parameters and which one? Please give the actual initial load (not an approximation, like “~800 EBs”; and not only a comparison “more/less than in A”) for each of the scenarios A,B,C.

5. The description of results from Fig.3 seems to imply the importance of the “initial load” for the outcome of ascension. That raises the following question: what was the initial load in the other results (Fig. 4-8) and how were these results affected by the initial load?

6. Lines 397-398: It is nice that the authors added these percentages in the text. It is a pity, however, that these cannot be “seen” in the plot. Could the authors add more labels on the axes (e.g. showing values between 0 and 0.05 on the horizontal axes and values between 0 and 0.25 on the vertical axes) to increase readability of the plots.

7. The authors use various terms for the disease chlamydia and the organism (C. trachomatis) causing the disease and sometimes use the same term for the disease and the organism. To avoid confusion, it is advisable to use distinct terms for the organism and the disease and to use these terms consistently throughout the manuscript.

**********

Have the authors made all data and (if applicable) computational code underlying the findings in their manuscript fully available?

The PLOS Data policy requires authors to make all data and code underlying the findings described in their manuscript fully available without restriction, with rare exception (please refer to the Data Availability Statement in the manuscript PDF file). The data and code should be provided as part of the manuscript or its supporting information, or deposited to a public repository. For example, in addition to summary statistics, the data points behind means, medians and variance measures should be available. If there are restrictions on publicly sharing data or code —e.g. participant privacy or use of data from a third party—those must be specified.

Reviewer #1: None

Reviewer #2: No: 

**********

PLOS authors have the option to publish the peer review history of their article (what does this mean?). If published, this will include your full peer review and any attached files.

If you choose “no”, your identity will remain anonymous but your review may still be made public.

Do you want your identity to be public for this peer review? For information about this choice, including consent withdrawal, please see our Privacy Policy.

Reviewer #1: No

Reviewer #2: No

Figure Files:

While revising your submission, please upload your figure files to the Preflight Analysis and Conversion Engine (PACE) digital diagnostic tool, https://pacev2.apexcovantage.com. PACE helps ensure that figures meet PLOS requirements. To use PACE, you must first register as a user. Then, login and navigate to the UPLOAD tab, where you will find detailed instructions on how to use the tool. If you encounter any issues or have any questions when using PACE, please email us at figures@plos.org.

Data Requirements:

Please note that, as a condition of publication, PLOS' data policy requires that you make available all data used to draw the conclusions outlined in your manuscript. Data must be deposited in an appropriate repository, included within the body of the manuscript, or uploaded as supporting information. This includes all numerical values that were used to generate graphs, histograms etc.. For an example in PLOS Biology see here: http://www.plosbiology.org/article/info%3Adoi%2F10.1371%2Fjournal.pbio.1001908#s5.

Reproducibility:

To enhance the reproducibility of your results, we recommend that you deposit your laboratory protocols in protocols.io, where a protocol can be assigned its own identifier (DOI) such that it can be cited independently in the future. Additionally, PLOS ONE offers an option to publish peer-reviewed clinical study protocols. Read more information on sharing protocols at https://plos.org/protocols?utm_medium=editorial-email&utm_source=authorletters&utm_campaign=protocols

References:

Review your reference list to ensure that it is complete and correct. If you have cited papers that have been retracted, please include the rationale for doing so in the manuscript text, or remove these references and replace them with relevant current references. Any changes to the reference list should be mentioned in the rebuttal letter that accompanies your revised manuscript.

If you need to cite a retracted article, indicate the article’s retracted status in the References list and also include a citation and full reference for the retraction notice.

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1009365.r005

Decision Letter 2

Rob J De Boer, Janneke Heijne

19 Aug 2021

Dear Dr. Huston,

We are pleased to inform you that your manuscript 'Ascension of Chlamydia is moderated by uterine peristalsis and the neutrophil response to infection' has been provisionally accepted for publication in PLOS Computational Biology.

Before your manuscript can be formally accepted you will need to complete some formatting changes, which you will receive in a follow up email. A member of our team will be in touch with a set of requests.

Please note that your manuscript will not be scheduled for publication until you have made the required changes, so a swift response is appreciated.

IMPORTANT: The editorial review process is now complete. PLOS will only permit corrections to spelling, formatting or significant scientific errors from this point onwards. Requests for major changes, or any which affect the scientific understanding of your work, will cause delays to the publication date of your manuscript.

Should you, your institution's press office or the journal office choose to press release your paper, you will automatically be opted out of early publication. We ask that you notify us now if you or your institution is planning to press release the article. All press must be co-ordinated with PLOS.

Thank you again for supporting Open Access publishing; we are looking forward to publishing your work in PLOS Computational Biology. 

Best regards,

Janneke Heijne, Ph.D.

Guest Editor

PLOS Computational Biology

Rob De Boer

Deputy Editor

PLOS Computational Biology

***********************************************************

PLoS Comput Biol. doi: 10.1371/journal.pcbi.1009365.r006

Acceptance letter

Rob J De Boer, Janneke Heijne

1 Sep 2021

PCOMPBIOL-D-20-02253R2

Ascension of Chlamydia is moderated by uterine peristalsis and the neutrophil response to infection

Dear Dr Huston,

I am pleased to inform you that your manuscript has been formally accepted for publication in PLOS Computational Biology. Your manuscript is now with our production department and you will be notified of the publication date in due course.

The corresponding author will soon be receiving a typeset proof for review, to ensure errors have not been introduced during production. Please review the PDF proof of your manuscript carefully, as this is the last chance to correct any errors. Please note that major changes, or those which affect the scientific understanding of the work, will likely cause delays to the publication date of your manuscript.

Soon after your final files are uploaded, unless you have opted out, the early version of your manuscript will be published online. The date of the early version will be your article's publication date. The final article will be published to the same URL, and all versions of the paper will be accessible to readers.

Thank you again for supporting PLOS Computational Biology and open-access publishing. We are looking forward to publishing your work!

With kind regards,

Katalin Szabo

PLOS Computational Biology | Carlyle House, Carlyle Road, Cambridge CB4 3DN | United Kingdom ploscompbiol@plos.org | Phone +44 (0) 1223-442824 | ploscompbiol.org | @PLOSCompBiol

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Supplementary Materials

    S1 Fig. A histogram of the amount of ascended bacteria under different distributional assumptions.

    Each histogram represents 12,625 simulations from the model, where the underlying distribution for the rate parameters has been selected from an exponential distribution, a gamma distribution and a log-normal distribution. All distributions have identical means of 1/100.

    (TIF)

    S1 Text. Provides information on the Parametrisation of key distributions.

    (DOCX)

    Attachment

    Submitted filename: ascensions_response_to_reviewers.docx

    Attachment

    Submitted filename: ascension_response_to_reviewers_R2.docx

    Data Availability Statement

    All relevant data are within the manuscript and its Supporting Information files.


    Articles from PLoS Computational Biology are provided here courtesy of PLOS

    RESOURCES